12 Feb CellProthera Acquires Full Rights to Transendocardial Catheter Developed by Celyad Oncology
Strategic acquisition secures proprietary stem cell delivery technology as CellProthera prepares for Phase 3 clinical development in...
Author: equipe
12 Feb It’s all about timing: CellProthera CEO talks CDMO partnership with CELLforCURE
For some companies, patience may be a virtue when it comes to collaboration.
25 Sep CellProthera announces peer-reviewed publication of its Phase I/IIb results on safety and feasibility of ProtheraCytes® in patients with severe heart failure post-myocardial Infarction
JACC-Heart Failure publication highlights high-quality cell expansion, good tolerability, manageable procedural risk and encouraging early signals of...
10 Sep Phase II results available now in JACC-HF
You can read the full article, here: https://www.sciencedirect.com/science/article/pii/S2213177925005542 ...
30 Jun CellProthera Collaborator Presents Phase 1/2b Quality-of-Life Results for ProtheraCytes® Cell Therapy at ISTH
Mulhouse, France, June 22, 2025 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, announces...